Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
EPIC: FUM
Market: AIM
52-week High/Low: 96.25p / 14.50p
Sector: Pharma & Biotech
Market Cap: 67.28M
Phone: +44 (0)1483 685 670
Address: Surrey Technology Centre, 40 Occam Road, Surrey Research Park, Guildford, Su
Website: www.futuramedical.co.uk
Futura Medical plc.

Futura Medical plc.

Futura's innovation strategy applies advanced science to develop products with compelling commercial potential using our advanced proprietary transdermal technology.
Based in Surrey, UK, the company's shares trade on the AIM market of the London Stock Exchange. Futura's development pipeline focuses on sexual healthcare and pain relief management and we are evaluating further therapeutic opportunities as potential additions to the pipeline. Futura is gaining recognition within the pharmaceutical industry for its strengths in transdermal drug delivery technology. We have relationships with a number of key players in the consumer healthcare market.

Futura Medical plc.

www.futuramedical.co.uk

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Futura Medical plc.


Futura Medical plc. Snapshot

Futura's innovation strategy applies advanced science to develop products with compelling commercial potential using our advanced proprietary transdermal technology.

Based in Surrey, UK, the company's shares trade on the AIM market of the London Stock Exchange. Futura's development pipeline focuses on sexual healthcare and pain relief management and we are evaluating further therapeutic opportunities as potential additions to the pipeline. Futura is gaining recognition within the pharmaceutical industry for its strengths in transdermal drug delivery technology. We have relationships with a number of key players in the consumer healthcare market.

Futura is actively working to expand its product portfolio both through internal product development and externally through focused product acquisition. If you believe you have a product under development that would be of interest to us, please write to Futura Medical Developments Limited, Surrey Technology Centre, 40 Occam Road, Guildford, Surrey, GU2 7YG or email us at [email protected]

Our products
Futura's innovation strategy applies advanced science to develop products with compelling commercial potential using our advanced proprietary transdermal technology

We focus exclusively on topically applied pharmaceutical drugs and medical devices. We only incorporate existing well-characterised chemical entities into our products. This strategy gives us a lower development risk profile compared with developing new chemical entities. As a result, the overall risk of the investment is reduced as our strategy increases the likelihood of regulatory approval and lowers the cost of development.

In addition to our developing portfolio of sexual healthcare and pain relief products we are looking at incorporating our proprietary delivery system DermaSys® into other products that may fall outside of these current areas provided that we believe they offer a compelling commercial opportunity.

We have six core products in our development pipeline for sexual healthcare and pain relief: CSD500, PET500, MED2002, TPR100, TIB200 and SPR300.

John Clarke - Non-Executive Chairman
Current roles: John Clarke became Chairman of Futura Medical plc on 1 February 2012. He is a member of the Nominations Committee and the Remuneration Committee. He is also the Non-Executive Chairman of Science in Sport plc and Quantum Pharma plc and a Non-Executive Director of Kind Consumer Ltd.
Past roles: Appointed President of GSK Consumer Healthcare in 2006, a position from which he stepped down in October 2011. Under his leadership, GSK Consumer Healthcare became one of the fastest-growing companies in its industry. Director of Provexis plc and of the US based Consumer Healthcare Products Association.
Brings to the Board: Extensive experience of the healthcare sector, having worked at GSK for more than 35 years.

James Barder - Chief Executive
Current roles: James Barder joined the Group as Chief Executive in June 2001. He assists the Remuneration Committee and the Nominations Committee (but is not a member of and does not vote on either). He has overall responsibility for all activities of the Group, is a principal contact for shareholder and investor relations matters and leads licensing and distribution negotiations. He first became involved with the Group in 1997. He is also a Non-Executive Director of Lorega Limited.
Past roles: Managing Director of Aon Capital Markets Limited. He has predominantly worked in the field of insurance and finance including firms he founded.
Brings to the Board: Over 25 years of experience in setting up, managing and running companies.

Derek Martin- Finance Director
Company Secretary

Current roles: Derek Martin joined the Board in September 2008. He oversees the Group's finance function its compliance procedures and is a principal contact for shareholder and investor relations matters.
Past roles: Senior financial roles in a diverse range of industries including retail, software, telecoms and advertising, media and sales promotion.
Brings to the Board: Over 25 years of experience in finance.


Jonathan Freeman, BA (Hons), MBA - Senior Independent Non-Executive Director and
Chairman of Remuneration Committee and Audit Committee
Current roles: Jonathan Freeman joined the Board in July 2003 and was appointed Senior Independent Non-Executive Director in November 2003. He chairs the Audit Committee and the Remuneration Committee and is also a member of the Nominations Committee. He is also an Executive Director of Braveheart Investment Group plc and a Director of PhotonStar LED Group plc.
Past roles: Director of Beeson Gregory, Chief Executive Officer of Syndicate Asset Management plc and a Director of Hume Securities plc.
Brings to the Board: Over 20 years of experience in the financial services sector, guidance on City regulatory matters, corporate finance and investor relations.

Lisa Arnold - Independent Non-Executive Director - Chair of Nominations Committee
Current roles: Lisa Arnold joined the Board in March 2008. She chairs the Nominations Committee and is also a member of the Remuneration Committee and the Audit Committee. She is also a non-executive Director of Pimco Europe and has a number of appointments on the boards of pension funds including Allied Domecq, Whitbread and Tate & Lyle.
Past roles: Senior investment banking analyst positions at NatWest Markets, UBS and Commerzbank. She has also worked in consultancy and Non-Executive roles in the pensions, healthcare and technology sectors and was most recently a Non-Executive Director of the UK's Medicines and Healthcare products Regulatory Agency ("MHRA"), for nine years where she also chaired the Risk & Audit Committee.
Brings to the Board: Over 20 years of experience of financial markets and healthcare sectors and associated governance frameworks.

For information on shares plese click here

+44 (0)1483 685 670

Address: Surrey Technology Centre,

40 Occam Road,

Surrey Research Park,

Guildford, Su

Nominated Adviser and broker N+1 Singer
1 Bartholomew Lane
London EC2N 2AX
  
Auditors BDO LLP

Kings Wharf
20-30 Kings Road
Reading
Berkshire RG1 3EX
  
Registrars Capita Asset Services
The Registry
34 Beckenham Road
Beckenham
Kent
BR3 4TU
  
Principal solicitors Memery Crystal LLP
44 Southampton Buildings
London WC2A 1AP
  
Patent attorneys Withers and Rogers LLP
4 More London Riverside
London
SE1 2AU
  
Principal bankers HSBC Bank
PO Box 160
12A North Street
Guildford
GU1 4AF

Futura Medical plc. Timeline

Columns Including FUM

VIEW ALL

Market Reports Including FUM

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.